BACKGROUND: A vaccine would be an ideal tool for reducing malaria's impact. PfSPZVaccine (radiation attenuated, aseptic, purified, cryopreserved Plasmodium falciparum [Pf] sporozoites [SPZ]) has been well tolerated and safe in >1526 malaria-naive and experienced 6-month to 65-year-olds in the United States, Europe, and Africa. When vaccine efficacy (VE) of 5 doses of 2.7 × 105 PfSPZ of PfSPZ Vaccine was assessed in adults against controlled human malaria infection (CHMI) in the United States and Tanzania and intense field transmission of heterogeneous Pf in Mali, Tanzanians had the lowest VE (20%). METHODS: To increase VE in Tanzania, we increased PfSPZ/dose (9 × 105 or 1.8 × 106) and decreased numbers of doses to 3 at 8-week intervals in a double blind, placebo-controlled trial. RESULTS: All 22 CHMIs in controls resulted in parasitemia by quantitative polymerase chain reaction. For the 9 × 105 PfSPZ group, VE was 100% (5/5) at 3 or 11 weeks (P < .000l, Barnard test, 2-tailed). For 1.8 × 106 PfSPZ, VE was 33% (2/6) at 7.5 weeks (P = .028). VE of dosage groups (100% vs 33%) was significantly different (P = .022). Volunteers underwent repeat CHMI at 37-40 weeks after last dose. 6/6 and 5/6 volunteers developed parasitemia, but time to first parasitemia was significantly longer than controls in the 9 × 105 PfSPZ group (10.89 vs 7.80 days) (P = .039), indicating a significant reduction in parasites in the liver. Antibody and T-cell responses were higher in the 1.8 × 106 PfSPZ group. CONCLUSIONS: In Tanzania, increasing the dose from 2.7 × 105 to 9 × 105 PfSPZincreased VE from 20% to 100%, but increasing to 1.8 × 106 PfSPZ significantly reduced VE. CLINICAL TRIALS REGISTRATION: NCT02613520.
RCT Entities:
BACKGROUND: A vaccine would be an ideal tool for reducing malaria's impact. PfSPZ Vaccine (radiation attenuated, aseptic, purified, cryopreserved Plasmodium falciparum [Pf] sporozoites [SPZ]) has been well tolerated and safe in >1526 malaria-naive and experienced 6-month to 65-year-olds in the United States, Europe, and Africa. When vaccine efficacy (VE) of 5 doses of 2.7 × 105 PfSPZ of PfSPZ Vaccine was assessed in adults against controlled humanmalaria infection (CHMI) in the United States and Tanzania and intense field transmission of heterogeneous Pf in Mali, Tanzanians had the lowest VE (20%). METHODS: To increase VE in Tanzania, we increased PfSPZ/dose (9 × 105 or 1.8 × 106) and decreased numbers of doses to 3 at 8-week intervals in a double blind, placebo-controlled trial. RESULTS: All 22 CHMIs in controls resulted in parasitemia by quantitative polymerase chain reaction. For the 9 × 105 PfSPZ group, VE was 100% (5/5) at 3 or 11 weeks (P < .000l, Barnard test, 2-tailed). For 1.8 × 106 PfSPZ, VE was 33% (2/6) at 7.5 weeks (P = .028). VE of dosage groups (100% vs 33%) was significantly different (P = .022). Volunteers underwent repeat CHMI at 37-40 weeks after last dose. 6/6 and 5/6 volunteers developed parasitemia, but time to first parasitemia was significantly longer than controls in the 9 × 105 PfSPZ group (10.89 vs 7.80 days) (P = .039), indicating a significant reduction in parasites in the liver. Antibody and T-cell responses were higher in the 1.8 × 106 PfSPZ group. CONCLUSIONS: In Tanzania, increasing the dose from 2.7 × 105 to 9 × 105 PfSPZ increased VE from 20% to 100%, but increasing to 1.8 × 106 PfSPZ significantly reduced VE. CLINICAL TRIALS REGISTRATION: NCT02613520.
Authors: Mahamadou S Sissoko; Sara A Healy; Abdoulaye Katile; Freda Omaswa; Irfan Zaidi; Erin E Gabriel; Bourama Kamate; Yacouba Samake; Merepen A Guindo; Amagana Dolo; Amadou Niangaly; Karamoko Niaré; Amatigue Zeguime; Kourane Sissoko; Hama Diallo; Ismaila Thera; Kelly Ding; Michael P Fay; Elise M O'Connell; Thomas B Nutman; Sharon Wong-Madden; Tooba Murshedkar; Adam J Ruben; Minglin Li; Yonas Abebe; Anita Manoj; Anusha Gunasekera; Sumana Chakravarty; B Kim Lee Sim; Peter F Billingsley; Eric R James; Michael Walther; Thomas L Richie; Stephen L Hoffman; Ogobara Doumbo; Patrick E Duffy Journal: Lancet Infect Dis Date: 2017-02-16 Impact factor: 25.071
Authors: K Haneda; K Sano; G Tamura; H Shirota; Y Ohkawara; T Sato; S Habu; K Shirato Journal: Am J Respir Cell Mol Biol Date: 1999-08 Impact factor: 6.914
Authors: Kirsten E Lyke; Andrew S Ishizuka; Andrea A Berry; Sumana Chakravarty; Adam DeZure; Mary E Enama; Eric R James; Peter F Billingsley; Anusha Gunasekera; Anita Manoj; Minglin Li; Adam J Ruben; Tao Li; Abraham G Eappen; Richard E Stafford; Natasha Kc; Tooba Murshedkar; Floreliz H Mendoza; Ingelise J Gordon; Kathryn L Zephir; LaSonji A Holman; Sarah H Plummer; Cynthia S Hendel; Laura Novik; Pamela J M Costner; Jamie G Saunders; Nina M Berkowitz; Barbara J Flynn; Martha C Nason; Lindsay S Garver; Matthew B Laurens; Christopher V Plowe; Thomas L Richie; Barney S Graham; Mario Roederer; B Kim Lee Sim; Julie E Ledgerwood; Stephen L Hoffman; Robert A Seder Journal: Proc Natl Acad Sci U S A Date: 2017-02-21 Impact factor: 11.205
Authors: Robert A Seder; Lee-Jah Chang; Mary E Enama; Kathryn L Zephir; Uzma N Sarwar; Ingelise J Gordon; LaSonji A Holman; Eric R James; Peter F Billingsley; Anusha Gunasekera; Adam Richman; Sumana Chakravarty; Anita Manoj; Soundarapandian Velmurugan; MingLin Li; Adam J Ruben; Tao Li; Abraham G Eappen; Richard E Stafford; Sarah H Plummer; Cynthia S Hendel; Laura Novik; Pamela J M Costner; Floreliz H Mendoza; Jamie G Saunders; Martha C Nason; Jason H Richardson; Jittawadee Murphy; Silas A Davidson; Thomas L Richie; Martha Sedegah; Awalludin Sutamihardja; Gary A Fahle; Kirsten E Lyke; Matthew B Laurens; Mario Roederer; Kavita Tewari; Judith E Epstein; B Kim Lee Sim; Julie E Ledgerwood; Barney S Graham; Stephen L Hoffman Journal: Science Date: 2013-08-08 Impact factor: 47.728
Authors: Markus Cornberg; Laurie L Kenney; Alex T Chen; Stephen N Waggoner; Sung-Kwon Kim; Hans P Dienes; Raymond M Welsh; Liisa K Selin Journal: Front Immunol Date: 2013-12-20 Impact factor: 7.561
Authors: Thomas L Richie; Peter F Billingsley; B Kim Lee Sim; Eric R James; Sumana Chakravarty; Judith E Epstein; Kirsten E Lyke; Benjamin Mordmüller; Pedro Alonso; Patrick E Duffy; Ogobara K Doumbo; Robert W Sauerwein; Marcel Tanner; Salim Abdulla; Peter G Kremsner; Robert A Seder; Stephen L Hoffman Journal: Vaccine Date: 2015-11-27 Impact factor: 3.641
Authors: Said A Jongo; L W Preston Church; Ali T Mtoro; Sumana Chakravarty; Adam J Ruben; Phillip A Swanson; Kamaka R Kassim; Maximillian Mpina; Anneth-Mwasi Tumbo; Florence A Milando; Munira Qassim; Omar A Juma; Bakari M Bakari; Beatus Simon; Eric R James; Yonas Abebe; Natasha Kc; Elizabeth Saverino; Linda Gondwe; Fabian Studer; Martina Fink; Glenda Cosi; Jill El-Khorazaty; David Styers; Robert A Seder; Tobias Schindler; Peter F Billingsley; Claudia Daubenberger; B Kim Lee Sim; Marcel Tanner; Thomas L Richie; Salim Abdulla; Stephen L Hoffman Journal: Am J Trop Med Hyg Date: 2019-06 Impact factor: 2.345
Authors: Seif Shekalaghe; Mastidia Rutaihwa; Peter F Billingsley; Mwajuma Chemba; Claudia A Daubenberger; Eric R James; Maximillian Mpina; Omar Ali Juma; Tobias Schindler; Eric Huber; Anusha Gunasekera; Anita Manoj; Beatus Simon; Elizabeth Saverino; L W Preston Church; Cornelus C Hermsen; Robert W Sauerwein; Christopher Plowe; Meera Venkatesan; Philip Sasi; Omar Lweno; Paul Mutani; Ali Hamad; Ali Mohammed; Alwisa Urassa; Tutu Mzee; Debbie Padilla; Adam Ruben; B Kim Lee Sim; Marcel Tanner; Salim Abdulla; Stephen L Hoffman Journal: Am J Trop Med Hyg Date: 2014-07-28 Impact factor: 2.345
Authors: Javier Ibanez; Rolf Fendel; Freia-Raphaella Lorenz; Patricia Granados-Bayon; Sina Brückner; Meral Esen; Mihály Sulyok; Zita Sulyok; Steffen Borrmann; Petra Bacher; Alexander Scheffold; Stephen L Hoffman; Peter G Kremsner; Benjamin Mordmüller Journal: NPJ Vaccines Date: 2022-05-31 Impact factor: 9.399
Authors: Joana C Silva; Ankit Dwivedi; Kara A Moser; Mahamadou S Sissoko; Judith E Epstein; Sara A Healy; Kirsten E Lyke; Benjamin Mordmüller; Peter G Kremsner; Patrick E Duffy; Tooba Murshedkar; B Kim Lee Sim; Thomas L Richie; Stephen L Hoffman Journal: Nat Commun Date: 2022-06-13 Impact factor: 17.694
Authors: Katharine A Collins; Florian Brod; Rebecca Snaith; Marta Ulaszewska; Rhea J Longley; Ahmed M Salman; Sarah C Gilbert; Alexandra J Spencer; David Franco; W Ripley Ballou; Adrian V S Hill Journal: Sci Rep Date: 2021-05-24 Impact factor: 4.379
Authors: Vicente Urbano Nsue Ndong Nchama; Ali Hamad Said; Ali Mtoro; Gertrudis Owono Bidjimi; Marta Alene Owono; Escolastica Raquel Mansogo Maye; Martin Eka Ondo Mangue; Genaro Nsue Nguema Okomo; Beltran Ekua Ntutumu Pasialo; Dolores Mbang Ondo; Maria-Silvia Angue Lopez; Fortunata Lobede Mochomuemue; Mariano Obiang Obono; Juan Carlos Momo Besaha; Raul Chuquiyauri; Said Abdallah Jongo; Kassim Kamaka; Ummi Abdul Kibondo; Thabit Athuman; Carlos Cortez Falla; Jeremías Nzamio Mba Eyono; Jordan Michael Smith; Guillermo A García; José Raso; Elizabeth Nyakarungu; Maxmillian Mpina; Tobias Schindler; Claudia Daubenberger; Laurence Lemiale; Peter F Billingsley; B Kim Lee Sim; Thomas L Richie; L W Preston Church; Ally Olotu; Marcel Tanner; Stephen L Hoffman; Salim Abdulla Journal: Malar J Date: 2021-07-20 Impact factor: 2.979
Authors: Peter F Billingsley; Kasim I George; Abraham G Eappen; Robert A Harrell; Robert Alford; Tao Li; Sumana Chakravarty; B Kim Lee Sim; Stephen L Hoffman; David A O'Brochta Journal: Malar J Date: 2021-06-26 Impact factor: 2.979